Abstract
We report the case of a 58-year-old man with multiple myeloma stage III A who received tandem autologous stem cell transplantation after induction by two courses of VAD and three cycles of bortezomib-dexamethasone, due to progression under chemotherapy. The second transplantation was complicated by severe hepatic veno-occlusive disease (HVOD). The patient received defibrotide with total recovery. The occurence of HVOD after conditioning by melphalan is uncommon and the role of bortezomib was questioned.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Boronic Acids / administration & dosage
-
Boronic Acids / adverse effects
-
Bortezomib
-
Dexamethasone / administration & dosage
-
Doxorubicin / administration & dosage
-
Etoposide / administration & dosage
-
Hepatic Veno-Occlusive Disease / chemically induced*
-
Humans
-
Male
-
Melphalan / administration & dosage
-
Melphalan / adverse effects*
-
Middle Aged
-
Multiple Myeloma / therapy
-
Myeloablative Agonists / administration & dosage
-
Myeloablative Agonists / adverse effects*
-
Pyrazines / administration & dosage
-
Pyrazines / adverse effects
-
Stem Cell Transplantation*
-
Transplantation Conditioning / adverse effects*
-
Transplantation, Autologous
Substances
-
Boronic Acids
-
Myeloablative Agonists
-
Pyrazines
-
Bortezomib
-
Etoposide
-
Dexamethasone
-
Doxorubicin
-
Melphalan